OpenNashEarnings

Roche (ROG) · Pharmaceuticals

Roche Q3 2026 earnings: summary, key numbers & outlook

Results filed 22 Oct 2026 · Quarter ended 30 Sep 2026

Slides (55 pages)Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Roche advanced up to 20 potential new medicines toward 2030 while FDA Priority Reviews for fenebrutinib and giredestrant set up multiple late-2026 launches in multiple sclerosis and breast cancer.

Roche's growth came from a broad base of medicines for severe disease: Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo led. Ocrevus's subcutaneous version now makes up over 20% of Ocrevus volume, and Vabysmo has reached about 1.5m patients. FDA approvals arrived for Tecentriq in colon cancer and Enspryng in thyroid eye disease, and Diagnostics won clearance for the Elecsys pTau217 Alzheimer's blood test.

Management is steering toward a late-stage pipeline of up to 20 new medicines by 2030, with fenebrutinib in multiple sclerosis, giredestrant in breast cancer and a push into obesity as the main bets. It says there is no patent cliff ahead. The tension is execution: older products like Perjeta, Kadcyla and Actemra keep eroding, Diagnostics faces China pricing reform, and several launches depend on pending FDA decisions.

No call transcript for this quarter, so this summary also draws on: Quartr ↗.

Slides & documents

Open the slide deck (PDF, 55 pages) ↗

Roche Q3 2026 slide deck, page 1Roche Q3 2026 slide deck, page 2Roche Q3 2026 slide deck, page 3Roche Q3 2026 slide deck, page 4Roche Q3 2026 slide deck, page 5Roche Q3 2026 slide deck, page 6

Showing the first 6 of 55 pages.

Results documents

Key numbers

Group sales, Q3 2026 (CHF millions)
16.1B

up 7% at constant exchange rates

Group sales, first nine months of 2026
CHF 46.5 billion

up 6% at constant exchange rates, up 1% in CHF

Segment or metricValueChange
Pharmaceuticals Division (9M, CHF millions)36.2Bup 7% at CER
Diagnostics Division (9M, CHF millions)10.3Bup 4% at CER
Ocrevus (9M, CHF millions)5.3Bup 7% at CER
Hemlibra (9M, CHF millions)3.8Bup 12% at CER
Xolair (9M, CHF millions)2.5Bup 20% at CER
Where each number comes from
  • Group sales, Q3 2026 (CHF millions): “Roche Group 14,918 6 15,654 8 14,722 6 15,642 5 16,129 7”
  • Group sales, first nine months of 2026: “In the first nine months of 2026, Roche sales were +6% at CER, +1% when reported in CHF, to CHF 46.5 billion due to strong demand for pharmaceutical products and diagnostic solutions.”
  • Pharmaceuticals Division (9M, CHF millions): “Pharmaceuticals Division 36,212 35,555 7 2 United States 18,712 18,798 5 0”
  • Diagnostics Division (9M, CHF millions): “Diagnostics Division 10,281 10,307 4 0 Roche Group 46,493 45,862 6 1”
  • Ocrevus (9M, CHF millions): “Ocrevus 5,317 7 3,581 5 1,136 9 - - 600 21 Hemlibra 3,750 12”
  • Hemlibra (9M, CHF millions): “Hemlibra 3,750 12 2,006 9 769 5 291 20 684 23 Vabysmo 3,196 10”
  • Xolair (9M, CHF millions): “Xolair 2,521 20 2,521 20 - - - - - - Phesgo 2,064 18 486 -1”

Copied from the press release ↗ and other documents in the company's results page ↗. A figure is published only if its sentence is in those documents.

Outlook

MetricPeriodOutlook
Loss-of-exclusivity sales impact2026roughly CHF 0.6bn

Key takeaways

  1. Fenebrutinib could be first oral high-efficacy MS drug

    The FDA accepted fenebrutinib filings in both relapsing and primary progressive MS with Priority Review. Roche says it would be the first BTK inhibitor and first high-efficacy oral treatment for both forms, challenging its own Ocrevus franchise's competitors and extending its MS reach.

  2. Giredestrant launch is imminent in breast cancer

    The FDA has PDUFA dates of 30 November 2026 for early-stage and 18 December 2026 for advanced breast cancer. The CEO says Roche is fully prepared to launch later this year, pending approval, as Perjeta and Kadcyla face pressure.

  3. Subcutaneous Ocrevus is shifting MS treatment to community practices

    Ocrevus Zunovo is the fastest growing aCD20 in the US, with about 60% of SC volume from community practices and over 56,000 patients treated globally. An on-body injector for twice-yearly at-home use has data expected in 2027.

  4. Roche is building an obesity franchise with two lead assets

    Positive phase II results for enicepatide and petrelintide in type 2 diabetes with overweight or obesity, plus phase III starts, support a stated ambition to become a top 3 obesity player. Hanmi and Rona partnerships added further obesity programs.

  5. Elecsys pTau217 uses existing lab instruments to reach primary care

    The FDA-cleared single-biomarker Alzheimer's blood test supports rule-in and rule-out across primary and specialty care. It is designed for Roche's installed base of more than 4,500 cobas instruments in the US.

Questions

What are Roche's most important near-term launches?

Giredestrant in breast cancer has FDA decision dates of 30 November and 18 December 2026, and fenebrutinib in multiple sclerosis is under FDA Priority Review. Enspryng in MOGAD has a PDUFA date of 10 January and vamikibart in uveitic macular edema by July 2027.

How is Ocrevus subcutaneous performing?

Ocrevus Zunovo has over 56,000 patients treated globally and accounts for more than 20% of Ocrevus volume. About 60% of US SC volume comes from community practices, and an on-body injector for twice-yearly at-home use has data expected in 2027.

What is Roche doing in obesity?

Roche reported positive phase II results for enicepatide and petrelintide in obesity with type 2 diabetes, with phase III programs under way or planned. It aims to become a top 3 player and added partnerships with Hanmi and Rona.

What is happening with Roche Diagnostics?

Elecsys pTau217 received FDA clearance as a single-biomarker Alzheimer's blood test, and the AXELIOS 1 sequencer launched in June 2026 with about a third of its year-one order target of 100 instruments achieved. China healthcare pricing reforms continue to weigh on Asia-Pacific sales.

Which Roche products are losing ground?

Perjeta is declining as customers convert to Phesgo, now at a 59% global conversion rate, while Kadcyla faces competitive pressure in the US and EU. Actemra is hit by biosimilars, and Roche expects a loss-of-exclusivity impact of roughly CHF 0.6bn in 2026.

Call recording

Listen to the official replay ↗